Innate Pharma S.A. (EPA:IPH)

Market Cap	171.06M
Revenue (ttm)	20.12M
Net Income (ttm)	-49.47M
Shares Out	92.16M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	3.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	118,814
Average Volume	248,135
Open	1.840
Previous Close	1.866
Day's Range	1.832 - 1.892
52-Week Range	1.330 - 2.500
Beta	0.96
RSI	63.88
Earnings Date	Sep 17, 2025

About Intra-Cellular Therapies

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 181
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPH

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.